Abstract
Purpose
As obesity and type 2 diabetes (T2D) have been increasing worldwide, we investigated their association with breast cancer incidence in the Reykjavik Study.
Methods
During 1968–1996, approximately 10,000 women (mean age = 53 ± 9 years) completed questionnaires and donated blood samples. T2D status was classified according to self-report (n = 140) and glucose levels (n = 154) at cohort entry. A linkage with the Icelandic Cancer Registry provided breast cancer incidence through 2015. Cox regression with age as time metric and adjusted for known confounders was applied to obtain hazard ratios (HR) and 95% confidence intervals (CI).
Results
Of 9,606 participants, 294 (3.1%) were classified as T2D cases at cohort entry while 728 (7.8%) women were diagnosed with breast cancer during 28.4 ± 11.6 years of follow-up. No significant association of T2D (HR 0.95; 95% CI 0.56–1.53) with breast cancer incidence was detected except among the small number of women with advanced breast cancer (HR 3.30; 95% CI 1.13–9.62). Breast cancer incidence was elevated among overweight/obese women without (HR 1.18; 95% CI 1.01–1.37) and with T2D (HR 1.35; 95% CI 0.79–2.31). Height also predicted higher breast cancer incidence (HR 1.03; 95% CI 1.02–1.05). All findings were confirmed in women of the AGES–Reykjavik sub-cohort (n = 3,103) who returned for an exam during 2002–2006. With a 10% T2D prevalence and 93 incident breast cancer cases, the HR for T2D was 1.18 (95% CI 0.62–2.27).
Conclusions
These findings in a population with low T2D incidence suggest that the presence of T2D does not confer additional breast cancer risk and confirm the importance of height and excess body weight as breast cancer risk factors.
Similar content being viewed by others
References
International Diabetes Federation (2017) IDF Diabetes Atlas 2017. https://www.diabetesatlas.org/. Accessed 21 Jun 2018.
Maskarinec G, Grandinetti A, Matsuura G et al (2009) Diabetes prevalence and body mass index differ by ethnicity: the Multiethnic Cohort. Ethn Dis 19:49–55
Barnes BB, Steindorf K, Hein R, Flesch-Janys D, Chang-Claude J (2011) Population attributable risk of invasive postmenopausal breast cancer and breast cancer subtypes for modifiable and non-modifiable risk factors. Cancer Epidemiol 35:345–352
Parkin DM, Boyd L, Walker LC (2011) The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer 105(Suppl 2): S77–S81
Sprague BL, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Hampton JM, Newcomb PA (2008) Proportion of invasive breast cancer attributable to risk factors modifiable after menopause. Am J Epidemiol 168:404–411
Bandera EV, Maskarinec G, Romieu I, John EM (2015) Racial and ethnic disparities in the impact of obesity on breast cancer risk and survival: a global perspective. Adv Nutr 6:803–819
Boyle P, Boniol M, Koechlin A et al (2012) Diabetes and breast cancer risk: a meta-analysis. Br J Cancer 107:1608–1617
Hsu WC, Boyko EJ, Fujimoto WY et al (2012) Pathophysiologic differences among Asians, native Hawaiians, and other Pacific Islanders and treatment implications. Diabetes Care 35:1189–1198
Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M (2018) Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol 6:e6–e15
Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856–862
Maskarinec G, Jacobs S, Park SY et al (2017) Type II diabetes, obesity, and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 26:854–861
Gunter MJ, Xie X, Xue X et al (2015) Breast cancer risk in metabolically healthy but overweight postmenopausal women. Cancer Res 75:270–274
Cust AE, Stocks T, Lukanova A et al (2009) The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat 113:567–576
Vilbergsson S, Sigurdsson G, Sigvaldason H, Hreidarsson AB, Sigfusson N (1997) Prevalence and incidence of NIDDM in Iceland: evidence for stable incidence among males and females 1967–1991–the Reykjavik Study. Diabet Med 14:491–498
Harris TB, Launer LJ, Eiriksdottir G et al (2007) Age, Gene/environment susceptibility-Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol 165:1076–1087
Jonsdottir LS, Sigfusson N, Gudnason V, Sigvaldason H, Thorgeirsson G (2002) Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. J Cardiovasc Risk 9:67–76
Thorbjarnardottir T, Olafsdottir EJ, Valdimarsdottir UA, Olafsson O, Tryggvadottir L (2014) Oral contraceptives, hormone replacement therapy and breast cancer risk: a cohort study of 16 928 women 48 years and older. Acta Oncol 53:752–758
Steingrimsdottir L, Halldorsson TI, Siggeirsdottir K et al (2014) Hip fractures and bone mineral density in the elderly–importance of serum 25-hydroxyvitamin D. PLoS ONE 9:e91122
Olafsdottir E, Aspelund T, Sigurdsson G et al (2009) Unfavourable risk factors for type 2 diabetes mellitus are already apparent more than a decade before onset in a population-based study of older persons: from the Age, Gene/Environment Susceptibility-Reykjavik Study (AGES-Reykjavik). Eur J Epidemiol 24:307–314
Genuth S, Alberti KG, Bennett P et al (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167
World Health Organization (1999) Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. https://apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf. Accessed 6 Mar 2018
Sigurdardottir LG, Jonasson JG, Stefansdottir S et al (2012) Data quality at the Icelandic cancer registry: comparability, validity, timeliness and completeness. Acta Oncol 51:880–889
Haraldsdottir A, Steingrimsdottir L, Valdimarsdottir UA et al (2017) Early life residence, fish consumption, and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 26:346–354
Knol MJ, VanderWeele TJ (2012) Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol 41:514–520
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578
van den Brandt PA, Spiegelman D, Yaun SS et al (2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152:514–527
Boyle P, Koechlin A, Pizot C et al (2013) Blood glucose concentrations and breast cancer risk in women without diabetes: a meta-analysis. Eur J Nutr 52:1533–1540
Phillips CM (2017) Metabolically healthy obesity across the life course: epidemiology, determinants, and implications. Ann N Y Acad Sci 1391:85–100
Stefan N, Haring HU, Schulze MB (2018) Metabolically healthy obesity: the low-hanging fruit in obesity treatment? Lancet Diabetes Endocrinol 6:249–258
Neeland IJ, Poirier P, Despres JP (2018) Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation 137:1391–1406
Olafsdottir E, Aspelund T, Sigurdsson G et al (2013) Similar decline in mortality rate of older persons with and without type 2 diabetes between 1993 and 2004 the Icelandic population-based Reykjavik and AGES-Reykjavik cohort studies. BMC Public Health 13:36
Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015 (2017) Lancet 390: 231–266
Barry E, Roberts S, Oke J, Vijayaraghavan S, Normansell R, Greenhalgh T (2017) Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions. BMJ 356:i6538
Walker JJ, Johnson JA, Wild SH (2013) Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure. Lancet Diabetes Endocrinol 1:132–139
Bergsveinsson J, Aspelund T, Gudnason V, Benediktsson R (2007) Prevalence of type 2 diabetes mellitus in Iceland 1967–2002. Laeknabladid 93:397–402
Acknowledgments
The AGES–Reykjavik Study was funded by NIH contract N01-AG-12100, the Intramural Research Program of the National Institute on Aging, the Icelandic Heart Association, and the Icelandic Parliament. This work was also supported by the Icelandic Centre for Research, RANNIS Grant Number: 152495051, https://en.rannis.is/ (to AH), and the Public Health Fund of the Icelandic Directorate of Health (to AH). GM was funded by a Fulbright Global Scholar Award (2017–2018).
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Maskarinec, G., Haraldsdóttir, Á., Einarsdóttir, K. et al. Type 2 diabetes and obesity in midlife and breast cancer risk in the Reykjavik cohort. Cancer Causes Control 30, 1057–1065 (2019). https://doi.org/10.1007/s10552-019-01213-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-019-01213-y